Skip Navigation LinksHome > May 2014 - Volume 21 - Issue 5 > Does hormone therapy affect blood pressure changes in the Di...
doi: 10.1097/GME.0b013e3182a0e3ea
Original Articles

Does hormone therapy affect blood pressure changes in the Diabetes Prevention Program?

Kim, Catherine MD, MPH1; Golden, Sherita H. MD, MHS2; Kong, Shengchun MS3; Nan, Bin PhD3; Mather, Kieren J. MD4; Barrett-Connor, Elizabeth MD5; Diabetes Prevention Program Research Group

Supplemental Author Material
Collapse Box


Objective: This study aims to examine whether blood pressure reductions differ by estrogen use among overweight glucose-intolerant women.

Methods: We conducted a secondary analysis of Diabetes Prevention Program postmenopausal participants who used oral estrogen with or without progestogen at baseline and 1-year follow-up (n = 324) versus those who did not use oral estrogen with or without progestogen at either time point (n = 382). Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) were examined by randomization arm (intensive lifestyle change [ILS], metformin 850 mg twice daily, or placebo). Associations between changes in blood pressure and changes in sex hormone–binding globulin, estradiol, testosterone, and dehydroepiandrosterone were also examined.

Results: Estrogen users and nonusers had similar prevalences of baseline hypertension (33% vs 34%, P = 0.82) and use of blood pressure medications at baseline (P = 0.25) and on follow-up (P = 0.10). Estrogen users and nonusers randomized to ILS had similar decreases in SBP (−3.3 vs −4.7 mm Hg, P = 0.45) and DBP (−3.1 vs −4.7 mm Hg, P = 0.16). Among estrogen users, women randomized to ILS had significant declines in SBP (P = 0.016) and DBP (P = 0.009) versus placebo. Among nonusers, women randomized to ILS had significant declines in DBP (P = 0.001) versus placebo, but declines in SBP were not significant (P = 0.11). Metformin was not associated with blood pressure reductions versus placebo regardless of estrogen therapy. Blood pressure changes were not associated with changes in sex hormones regardless of estrogen therapy.

Conclusions: Among overweight women with dysglycemia, the magnitude of blood pressure reductions after ILS is unrelated to postmenopausal estrogen use.

© 2014 by The North American Menopause Society.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.